Loading organizations...
Loading organizations...
Convalife Pharmaceuticals: Pharmaceutical company developing bispecific antibody biological drugs and small molecule drugs for solid tumor treatments.
Convalife Pharmaceuticals is a Shanghai, China-based biotechnology company that develops bispecific antibody biological drugs and small molecule therapeutics for the treatment of solid tumors. The organization's clinical product pipeline specifically targets severe oncology indications, providing therapeutic options for patients diagnosed with breast, prostate, pancreatic, liver, gastric, and lung cancers. Operating as a Series B stage venture, the enterprise has filed three patents, recently securing a formal grant in March 2025 for pharmaceutical compositions containing phosphoinositide 3-kinase inhibitors. The company has secured equity financing from a syndicate of institutional backers, featuring recognizable investors such as Jointown Pharmaceutical Group, Shangyu International Investment, and Hiway Capital. Additionally, the firm was noted in a regulatory filing by Puma Biotechnology regarding an Abbreviated New Drug Application challenge in the oncology sector. Convalife Pharmaceuticals was established in 2015 by currently undisclosed founders.
Convalife Pharmaceuticals has raised $100.0M across 1 funding round.
Convalife Pharmaceuticals has raised $100.0M in total across 1 funding round.
Convalife Pharmaceuticals has raised $100.0M in total across 1 funding round.
Convalife Pharmaceuticals's investors include Xicheng Zhiyuan.
Convalife Pharmaceuticals has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 4, 2024 | $100.0M Series C | Xicheng Zhiyuan |